ClinicalTrials.gg
Active, not recruitingNCT06417814TROPION-Lung15Updated Oct 15, 2026

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Phase 3 interventional study of Dato-DXd and Osimertinib in Metastatic Non-small Cell Lung Cancer, sponsored by AstraZeneca. Active, not recruiting at 211 sites in 24 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Updated Oct 15, 2026Now Active, not recruitingNo longer in Netherlands, Portugal and Romania+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
768
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 20 under way, 9 of them phase 3. datopotamab deruxtecan · Carcinoma, Non-Small-Cell Lung.

Enrollment
4th of 22
768 · median 273
Started
2024
with 3 others
Phase 3
9 of 22
3 open now
Primary completion
2027-01
later than 6 of 19 live
Registered
15th of 22
by date
Lead sponsor
12 of 22
AstraZeneca

Among the 22 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by enrollment, is one of 4 that started in 2024, is one of 9 in phase 3, reaches primary completion later than 6 of the 19 other live ones, and was the 15th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 22 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About datopotamab deruxtecan

datopotamab deruxtecan: first FDA approval 2025 (DATROWAY), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).

Read the detailed description

This is a Phase III, open-label, 3-arm, multicenter study assessing the effects of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in participants with epidermal growth factor receptor gene mutation (EGFRm) locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on prior osimertinib treatment.

Participants will be randomized in a 1:1:1 ratio to one of the following intervention groups:

  1. Dato-DXd + osimertinib combination therapy
  2. Dato-DXd monotherapy
  3. Platinum-based doublet chemotherapy

Participants will receive study intervention until Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) -defined radiological progression by the investigator, unacceptable toxicity, or other discontinuation criterion is met.

After study intervention discontinuation, all participants will undergo an end of treatment (EoT) visit within 35 days of discontinuation and will be followed up for safety assessments 28 (+ 7) days after their last dose of study intervention.

03

Conditions studied

  • Metastatic Non-small Cell Lung Cancer

Keywords

  • Epidermal growth factor receptor gene mutation
  • Standard of Care
  • Locally, advanced carcinoma
  • Metastatic carcinoma
  • Non-small cell lung cancer
  • Dato-dxd
  • Datopotamab deruxtecan
  • Osimertinib
  • Tagrisso
  • Pemetrexed
  • Carboplatin
  • Cisplatin
04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - or cytologically confirmed non-squamous NSCLC.
  • - Must have evidence of documented pre-existing EGFRm information (EGFRm known to be associated with (epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor [TKis] sensitivity [Ex19del, L858R, G719X, S768I, or L861Q], either alone or in combination with other EGFR mutations, which may include T790M).
  • - Documented extra-cranial radiologic progression on prior osimertinib monotherapy (as most recent ) in the adjuvant, locally advanced, or setting.
  • - Less than or equal to (\<=2) prior lines of EGFR TKIs (osimertinib is the only permitted prior third generation EGFR TKI).
  • - At least one lesion, not previously irradiated, that qualifies as a v1.1 TL at baseline and can be accurately measured at baseline.
  • - World Health Organization (WHO)/ (ECOG) performance status of 0 or 1.
  • - Adequate bone marrow reserve and organ function within 7 days before randomization.

Exclusion criteria

Exclusion Criteria:

  • - Use of chemotherapy, vascular endothelial growth factor inhibitor, immunotherapy or any anti-cancer therapy in the setting. Platinum-based chemotherapy in non-metastatic setting within 12 months prior to randomization.
  • - History of another primary except for malignancy treated with curative intent with no known active disease within 2 years before the first dose of study intervention.
  • - Any evidence of severe or uncontrolled systemic diseases, including, but not limited to active bleeding diseases, active infection, active ILD/pneumonitis, cardiac disease.
  • - Has significant third-space fluid retention (example [eg.], ascites or pleural effusion) as judged by the investigator and is not amenable for required repeated drainage.
  • - History of non-infectious ILD/pneumonitis including radiation pneumonitis that required or drug-induced ILD, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
  • - Has severe pulmonary function compromise resulting from intercurrent pulmonary illnesses.
  • -Unstable spinal cord compression and/or unstable .
  • - Participants with symptomatic brain metastases (including ).
  • - corneal disease.
  • - Uncontrolled infection requiring systemic antibiotics, antivirals, or antifungals, suspected infections or inability to rule out infections. Use of systemic antibiotics within 14 days of randomization.
  • - Has known (HIV) infection that is not well controlled.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
768 participants (actual)

Study arms

  • Experimental
    Group 1: Dato-DXd + Osimertinib Combination Therapy

    Participants will receive Dato-DXd 6 milligrams per kilogram (mg/kg) as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of every 21-day cycle, and osimertinib 80 milligrams (mg) once daily (QD) orally, until RECIST v1.1-defined radiological progression by investigator, unacceptable toxicity, or other discontinuation criterion is met.

    Drug: Dato-DXd · Drug: Osimertinib

  • Experimental
    Group 2: Dato-DXd Monotherapy

    Participants will receive Dato-DXd 6 mg/kg as IV infusion Q3W on Day 1 of every 21-day cycle, until RECIST v1.1-defined radiological progression by investigator, unacceptable toxicity, or other discontinuation criterion is met.

    Drug: Dato-DXd

  • Experimental
    Group 3: Platinum-based Doublet Chemotherapy

    Participants will receive pemetrexed 500 milligrams per meter square (mg/m2) in combination with carboplatin (AUC5) or cisplatin 75 mg/m2 as IV infusion Q3W for 4 cycles followed by pemetrexed maintenance 500 mg/m2 as IV infusion Q3W, until RECIST v1.1-defined radiological progression by investigator, unacceptable toxicity, or another discontinuation criterion is met.

    Drug: Pemetrexed · Drug: Carboplatin · Drug: Cisplatin

Interventions

  • Dato-DXd will be administered as IV infusion.

    Also known as: DS-1062a

  • Osimertinib will be administered orally.

    Also known as: Tagrisso, AZD9291

  • Pemetrexed will be administered as IV infusion.

  • Carboplatin will be administered as IV infusion.

  • Cisplatin will be administered as IV infusion.

06

What researchers measure

Primary outcomes

  1. Progression free Survival (PFS)

    PFS is defined as the time from randomization to Blinded Independent Central Review (BICR)-assessed progression using RECIST v1.1 or death due to any cause, regardless of whether the participant withdraws from study therapy, receives other anti-cancer therapy, or clinical progression.

    Time frame: Up to 2.5 years

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as time from randomization until the date of death due to any cause.

    Time frame: Up to 3.5 years

  2. Central Nervous System Progression-free Survival (CNS PFS)

    CNS PFS is defined as the time from randomization to BICR confirmed progression in the CNS or death due to any cause, regardless of whether the participant withdraws from study therapy, receives other anti-cancer therapy, or clinically progresses prior to BICR confirmed CNS modified RECIST v1.1 progression.

    Time frame: Up to 2.5 years

  3. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants who have a confirmed complete response (CR) or confirmed partial response (PR), as determined by BICR per RECIST v1.1.

    Time frame: Up to 2.5 years

  4. Duration of Response (DoR)

    DoR is defined as the time from the date of first documented response until date of documented progression per RECIST v1.1, as assessed by BICR or death due to any cause.

    Time frame: Up to 2.5 years

  5. Progression-free Survival-2 (PFS-2)

    PFS2 is defined as the time from randomization to the earliest of the progression event (following the initial investigator assessed progression), after first subsequent therapy, or death.

    Time frame: Up to 3.5 years

  6. Objective Response Rate (ORR) Using CNS Modified RECIST v1.1

    ORR is defined as the percentage of participants who have a confirmed CR or confirmed PR, using CNS modified RECIST v1.1.

    Time frame: Up to 2.5 years

  7. Duration of Response (DoR) Using CNS Modified RECIST v1.1

    DoR is defined as the time from the date of first documented response until date of documented progression or death due to any cause using CNS modified RECIST v1.1.

    Time frame: Up to 2.5 years

  8. Time to Deterioration in Pulmonary Symptoms

    Time to deterioration (in pulmonary symptoms \[dyspnea, cough, and chest pain\]) is defined as the time from randomization until the date of deterioration. Deterioration is defined as change from baseline that reaches a meaningful change threshold.

    Time frame: Up to 3.5 years

  9. Time to Deterioration in Physical Functioning

    Time to deterioration in physical functioning as measured by Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function short form 8c will be evaluated. Time to deterioration (in physical functionating) is defined as the time from randomization until the date of deterioration. Deterioration is defined as change from baseline that reaches a meaningful change threshold.

    Time frame: Up to 3.5 years

  10. Time to Deterioration in Global Health Status (GHS)/Quality of Life (QoL)

    Time to deterioration in GHS/QoL as measured by the GHS/QoL scale from EORTC IL172 will be reported. Time to deterioration (in GHS/QoL) is defined as the time from randomization until the date of deterioration. Deterioration is defined as change from baseline that reaches a meaningful change threshold.

    Time frame: Up to 3.5 years

  11. Pharmacokinetics (PK) of Dato-DXd

    Concentration of Dato-DXd, total anti-TROP2 antibody and DXd in plasma.

    Time frame: Up to 3.5 years

  12. Immunogenicity of Dato-DXd

    Presence of antidrug antibody (ADAs) for Dato-DXd (confirmatory results: positive or negative, titers).

    Time frame: Up to 3.5 years

07

Study locations

211 sites
  • Research Site
    Fayetteville, Arkansas 72703, United States
  • Research Site
    Fountain Valley, California 92708, United States
  • Research Site
    San Diego, California 92123, United States
  • Research Site
    Jacksonville, Florida 32256, United States
  • Research Site
    Kansas City, Missouri 64132, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Maumee, Ohio 43537, United States
  • Research Site
    Pittsburgh, Pennsylvania 15232, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Fitzroy, VIC3065, Australia
  • Research Site
    Heidelberg, 3084, Australia
  • Research Site
    Kogarah, 2217, Australia
  • Research Site
    Liverpool, 2170, Australia
  • Research Site
    Nedlands, 6009, Australia
  • Research Site
    St Leonards, 2065, Australia
  • Research Site
    Westmead, 2145, Australia
  • Research Site
    Woolloongabba, 4102, Australia
  • Research Site
    Charleroi, 6060, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Hasselt, 3500, Belgium
  • Research Site
    Jette, 1090, Belgium
  • Research Site
    Namur, 5000, Belgium
  • Research Site
    Roeselare, 8800, Belgium
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Betim, 32671-550, Brazil
  • Research Site
    Porto Alegre, 90470-340, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Rio de Janeiro, 22250-905, Brazil
  • Research Site
    Rio de Janeiro, 22281-100, Brazil
  • Research Site
    Rio de Janeiro, 22775-001, Brazil
  • Research Site
    São Paulo, 01327-001, Brazil
  • Research Site
    Brampton, Ontario L6R 3J7, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M5G 1Z5, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Québec, Quebec G1R 2J6, Canada
  • Research Site
    Baoding, 071000, China
  • Research Site
    Beijing, 100005, China
  • Research Site
    Beijing, 100034, China
  • Research Site
    Beijing, 100050, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Beijing, 101199, China
  • Research Site
    Bengbu, 233004, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Deyang, 618000, China
  • Research Site
    Ganzhou, 341099, China
  • Research Site
    Guangzhou, 510180, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Hengyang, 421001, China
  • Research Site
    Jinan, 250013, China
  • Research Site
    Linyi, 276000, China
  • Research Site
    Luoyang, 471003, China
  • Research Site
    Luzhou, 646000, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Shanghai, 200433, China
  • Research Site
    Shantou, China
  • Research Site
    Shenyang, 110004, China
  • Research Site
    Shenyang, 110042, China
  • Research Site
    Tianjin, CN-300052, China
  • Research Site
    Weifang, 261000, China
  • Research Site
    Wuhan, 430060, China
  • Research Site
    Zhengzhou, 450000, China
  • Research Site
    Zhengzhou, 450001, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Bordeaux, 33076, France
  • Research Site
    Caen, 14000, France
  • Research Site
    Lille, 59037, France
  • Research Site
    Montpellier, 34298, France
  • Research Site
    Nantes, 44093, France
  • Research Site
    Paris, 75014, France
  • Research Site
    Pessac, 33604, France
  • Research Site
    Toulon Armees, 83800, France
  • Research Site
    Toulouse, 31400, France
  • Research Site
    Villejuif, 94805, France
  • Research Site
    Berlin-Zehlendorf, 14165, Germany
  • Research Site
    Essen, 45122, Germany
  • Research Site
    Georgsmarienhütte, 49124, Germany
  • Research Site
    Großhansdorf, 22927, Germany
  • Research Site
    Hamburg, 20251, Germany
  • Research Site
    Hamburg, 21075, Germany
  • Research Site
    Löwenstein, 74245, Germany
  • Research Site
    Nuremberg, 90419, Germany
  • Research Site
    Athens, 11526, Greece
  • Research Site
    Athens, 11527, Greece
  • Research Site
    Thessaloniki, 552 36, Greece
  • Research Site
    Thessaloniki, 57001, Greece
  • Research Site
    Thessaloniki, 57010, Greece
  • Research Site
    Hong Kong, 999077, Hong Kong
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    Hyderabad, 500034, India
  • Research Site
    Kolhāpur, 416234, India
  • Research Site
    Mumbai, 400012, India
  • Research Site
    Namakkal, 637001, India

Showing the first 100 of 211 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Tan DS, Nadal E, Cheema P, Wu YL, Ahn MJ, Tanizaki J, Grainger E, Nizialek E, Forcina A, van der Gronde T, Yu HA. TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib. Ther Adv Med Oncol. 2025 Dec 23;17:17588359251385410. doi: 10.1177/17588359251385410. eCollection 2025. PubMed 41466843 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Jan 2027, 27 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 27 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jan 2027, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2024
First posted
May 16, 2024
StartActual
Oct 4, 2024
Primary completionEst.
Jan 11, 2027was Sep 2026
CompletionEst.
Sep 27, 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 15, 2026
Sites
92 sites removed; no longer in Netherlands, Portugal and Romania
Show 92 removed
  • Research Site · Duarte, United States
  • Research Site · La Jolla, United States
  • Research Site · Los Angeles, United States
  • Research Site · Colorado Springs, United States
  • Research Site · Fort Collins, United States
  • Research Site · Washington D.C., United States
  • Research Site · Gainesville, United States
  • Research Site · Athens, United States
  • Research Site · Chicago, United States
  • Research Site · Evanston, United States
  • Research Site · Louisville, United States
  • Research Site · Baltimore, United States
  • Research Site · Bethesda, United States
  • Research Site · Boston, United States
  • Research Site · Boston, United States
  • Research Site · Detroit, United States
  • Research Site · Omaha, United States
  • Research Site · Morristown, United States
  • Research Site · Northfield, United States
  • Research Site · New York, United States
  • Research Site · The Bronx, United States
  • Research Site · Philadelphia, United States
  • Research Site · Chattanooga, United States
  • Research Site · Fairfax, United States
  • Research Site · Seattle, United States
  • Research Site · Port Macquarie, Australia
  • Research Site · Woodville, Australia
  • Research Site · La Louvière, Belgium
  • Research Site · Leuven, Belgium
  • Research Site · Blumenau, Brazil
  • …and 62 more on the registry record
Oct 15, 2026
Primary completion
Sep 30, 2026→Jan 11, 2027
Oct 15, 2026
Enrollment
744 (estimated)→768 (actual)
Oct 15, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • Edited-Unstable spinal cord compression and/or unstable brain metastases.
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Recruiting→Active, not recruiting
    92 sites removed; no longer in Netherlands, Portugal and Romania
    Show 92 removed
    • Research Site · Duarte, United States
    • Research Site · La Jolla, United States
    • Research Site · Los Angeles, United States
    • Research Site · Colorado Springs, United States
    • Research Site · Fort Collins, United States
    • Research Site · Washington D.C., United States
    • Research Site · Gainesville, United States
    • Research Site · Athens, United States
    • Research Site · Chicago, United States
    • Research Site · Evanston, United States
    • Research Site · Louisville, United States
    • Research Site · Baltimore, United States
    • Research Site · Bethesda, United States
    • Research Site · Boston, United States
    • Research Site · Boston, United States
    • Research Site · Detroit, United States
    • Research Site · Omaha, United States
    • Research Site · Morristown, United States
    • Research Site · Northfield, United States
    • Research Site · New York, United States
    • Research Site · The Bronx, United States
    • Research Site · Philadelphia, United States
    • Research Site · Chattanooga, United States
    • Research Site · Fairfax, United States
    • Research Site · Seattle, United States
    • Research Site · Port Macquarie, Australia
    • Research Site · Woodville, Australia
    • Research Site · La Louvière, Belgium
    • Research Site · Leuven, Belgium
    • Research Site · Blumenau, Brazil
    • …and 62 more on the registry record
    Primary completion Sep 30, 2026→Jan 11, 2027
    Enrollment 744 (estimated)→768 (actual)
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • Edited-Unstable spinal cord compression and/or unstable brain metastases.
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06417814
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
May 16, 2024
Start date
Oct 4, 2024
Primary completion
Jan 11, 2027 (estimated)
Completion
Sep 27, 2028 (estimated)
Last update
Oct 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Datopotamab deruxtecan · Pemetrexed · Carboplatin · Cisplatin

Start the discussion